Waters Corporation logo
Waters Corporation (WAT)
Compare

Waters Corporation (WAT) Debt to Equity Ratio: 0.58

Is Waters Corporation’s debt to equity ratio high or low?

Waters Corporation's debt to equity ratio of 0.58 is 80% below its 5-year average of 2.93, near the low end of its 5-year range (0.58–6.26).

The debt to equity ratio for Waters Corporation (WAT) is 0.58 as of Wednesday, June 10, 2026. It is below its 12-month average by 23.18% (0.76).

WAT Debt to Equity Ratio Chart

WAT Debt to Equity Ratio
0.58-37.63% 1Y
Zoom

WAT Average Debt to Equity Ratio Chart

WAT Current vs Average Debt to Equity Ratio Chart

WAT Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

0.58

DEBT TO EQUITY RATIO AVG TTM

0.76

DEBT TO EQUITY RATIO AVG 3Y

1.73

DEBT TO EQUITY RATIO AVG 5Y

2.93

DEBT TO EQUITY RATIO AVG 10Y

2.08

DEBT TO EQUITY RATIO AVG 15Y

1.64

DEBT TO EQUITY RATIO AVG 20Y

1.65

CURRENT VS TTM AVG

-23.18%

CURRENT VS 3Y AVG

-66.52%

CURRENT VS 5Y AVG

-80.17%

CURRENT VS 10Y AVG

-72.08%

CURRENT VS 15Y AVG

-64.66%

CURRENT VS 20Y AVG

-64.93%

WAT Competitors' Debt to Equity Ratio

NAMEMARKET CAPDEBT TO EQUITY RATIOTTM3Y5Y
Waters Corporation (WAT)0.580.761.732.93
Mettler-Toledo International Inc. (MTD)$22.85B-99.1448.2326.0617.96
BioNTech SE (BNTX)$21.81B0.010.010.010.04
Veeva Systems Inc. (VEEV)$27.37B0.010.010.010.02
Biogen Inc. (BIIB)$29.00B0.380.390.440.53
DexCom, Inc. (DXCM)$29.24B0.510.871.001.01
Moderna, Inc. (MRNA)$18.40B0.220.150.110.10
IQVIA Holdings Inc. (IQV)$30.60B2.492.412.342.26
Hologic, Inc. (HOLX)$16.97B0.520.520.550.69
Centene Corporation (CNC)$31.94B0.940.840.830.81

Financial Health

Debt/Equity

0.58

Current Ratio

1.73

Waters Corporation Debt to Equity Ratio Formula & Definition

Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Waters Corporation Debt to Equity Ratio FAQ

What is the debt to equity ratio for Waters Corporation (WAT)?
The debt to equity ratio for WAT stock is 0.58.
Is Waters Corporation's debt to equity ratio high or low?
Waters Corporation's debt to equity ratio of 0.58 is 80% below its 5-year average of 2.93, near the low end of its 5-year range (0.58–6.26).
What is the TTM average debt to equity ratio for Waters Corporation (WAT)?
The TTM average debt to equity ratio for WAT stock is 0.76.
What is the 3Y average debt to equity ratio for Waters Corporation (WAT)?
The 3Y average debt to equity ratio for WAT stock is 1.73.
What is the 5Y average debt to equity ratio for Waters Corporation (WAT)?
The 5Y average debt to equity ratio for WAT stock is 2.93.
What is the 10Y average debt to equity ratio for Waters Corporation (WAT)?
The 10Y average debt to equity ratio for WAT stock is 2.08.
What is the 15Y average debt to equity ratio for Waters Corporation (WAT)?
The 15Y average debt to equity ratio for WAT stock is 1.64.
What is the 20Y average debt to equity ratio for Waters Corporation (WAT)?
The 20Y average debt to equity ratio for WAT stock is 1.65.

Waters Corporation Debt to Equity Ratio History

DATEDEBT TO EQUITY RATIO
2025-12-310.58
2024-12-310.93
2023-12-312.12
2022-12-313.30
2021-12-314.36
2020-12-316.26
2018-12-310.73
2017-12-310.89
2016-12-310.79
2015-12-310.81
2014-12-310.77
2013-12-310.75
2012-12-310.80
2011-12-310.81
2010-12-310.72
2009-12-310.74
2008-12-310.81
2007-12-311.51
2006-12-312.49
2005-12-312.91
2004-12-310.67
2003-12-310.42
2002-12-310.01
2001-12-310.00
2000-12-310.01
1999-12-310.33
1998-12-311.40
1997-12-314.44
1996-12-313.26

About Waters Corporation

Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA. Under its Waters segment, it engineers, manufactures, sells, and provides support for high and ultra-performance liquid chromatography and mass spectrometry (MS) systems. This includes essential consumables like chromatography columns and comprehensive post-warranty service plans. The TA segment focuses on designing, producing, selling, and servicing instruments for thermal analysis, rheometry, and calorimetry. Additionally, Waters develops and supplies sophisticated software that integrates with both its own instruments and those from other manufacturers. The company's advanced MS technology plays a crucial role in various applications, such as drug discovery and development (including clinical trial assessments), analyzing proteins involved in disease processes, ensuring nutritional safety, and conducting environmental testing. Its thermal analysis, rheometry, and calorimetry instruments are vital for assessing the suitability and stability of a wide range of materials, including fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids. These instruments support diverse sectors like industrial manufacturing, consumer goods, healthcare products, and life science research. Waters' extensive client base spans the life sciences, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental sectors, where its products are instrumental in research and development, quality assurance, and general laboratory operations. Established in 1958, Waters Corporation is headquartered in Milford, Massachusetts.

Milford, MA
7,600 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Udit Batra